Multicyclic PARP1-Selective Compounds to Reduce Cancer Adverse Events
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PARP inhibitors, such as PARP1/2 inhibitors, cause adverse events due to non-selective inhibition of PARP2, leading to dose reductions and discontinuation in cancer patients, while potentially offering limited antitumor activity across various cancer types.
Innovation Solution
Development of PARP1-selective small molecules that inhibit PARP1 activity, minimizing adverse events and maintaining antitumor efficacy by targeting PARP1 specifically.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PARP1/2 inhibitors are used to treat cancer, then antitumor activity is achieved, but adverse events occur due to non-selective inhibition of PARP2
Solution Approach 1:
The patent segments the target into two distinct parts: PARP1 and PARP2. The invention designs inhibitors that specifically target PARP1 while sparing PARP2, thereby separating the therapeutic effect (antitumor activity through PARP1 inhibition) from the adverse effects (caused by PARP2 inhibition). This selectivity allows the drug to maintain efficacy while reducing toxicity.
Solution Approach 2:
The patent applies local quality by creating inhibitors with specific molecular characteristics that confer selectivity for PARP1 over PARP2. The chemical structure is optimized to interact preferentially with PARP1's active site, providing localized specificity at the molecular level. This ensures that the inhibitory action is concentrated on the desired target (PARP1) while minimizing off-target effects.
2Object-affected harmful factors
If dose reductions are made to reduce adverse events, then safety is improved, but antitumor efficacy is reduced
Solution Approach 1:
By segmenting the inhibition profile to affect only PARP1 and not PARP2, the invention allows maintenance of therapeutic doses without the adverse events that previously forced dose reductions. The selective mechanism decouples the relationship between dose and toxicity, enabling full dosing while preserving safety.
Solution Approach 2:
The patent changes the key parameter of inhibitor selectivity from non-selective (affecting both PARP1 and PARP2) to selective (affecting only PARP1). This parameter change in molecular specificity allows the drug to maintain effective concentrations without triggering the adverse events that would otherwise require dose reduction.
3Adaptability or versatility
If current PARP inhibitors are used, then broad antitumor activity is achieved, but limited efficacy across various cancer types is observed
Solution Approach 1:
The patent applies local quality by optimizing the inhibitor's molecular properties to achieve superior PARP1 selectivity. This localized precision in target engagement enhances the quality of the drug-target interaction, leading to improved therapeutic outcomes and greater efficacy across multiple cancer types compared to non-selective inhibitors.
Data Source
AI summary
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.